Loading...
Loading...
CALC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 22.3M |
| Operating I/L | -22.3M |
| Other Income/Expense | 3.1M |
| Interest Income | 0.0M |
| Pretax | -19.3M |
| Income Tax Expense | -3.2M |
| Net Income/Loss | -19.3M |
CalciMedica, Inc. is a clinical-stage biotechnology company specializing in developing therapies for life-threatening inflammatory diseases. The company's proprietary technology targets the inhibition of calcium release-activated (CRAC) channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora, is an intravenous-formulated CRAC channel inhibitor designed for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.
